MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

Nature Medicine

Volumn 5, Issue 9, 1999, Pages 1048-1051

  Schuetz, John D ^a   Connelly, Michele C ^a   Sun, Daxi ^a   Paibir, Sheela G ^a   Flynn, Patricia M ^a   Srinivas, R V ^a   Kumar, Alok ^a   Fridland, Arnold ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DIDANOSINE; LAMIVUDINE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CROSS RESISTANCE; DRUG TRANSPORT; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; VIRUS MUTATION;

ADENINE; ANTI-HIV AGENTS; CARRIER PROTEINS; CELL LINE; DRUG RESISTANCE, MICROBIAL; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENES, DOMINANT; HIV-1; HUMANS; HYBRID CELLS; INHIBITORY CONCENTRATION 50; MEMBRANE TRANSPORT PROTEINS; NUCLEOSIDES; PHENOTYPE; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, MESSENGER; T-LYMPHOCYTES; ZIDOVUDINE;

EID: 0032879904     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/12487     Document Type: Article

References (22)

1. Berger, E. A., Moss, B. & Pastan, I. Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART. Proc. Natl. Acad. Sci. USA 95, 11511-11513 (1998).
2. Groschel, B., Cinatl, J. & Cinatl, J.Jr. Viral and cellular factors for resistance against antiretroviral agents. Intervirology 40, 400-407 (1997).
3. Plotkin, S.A., Drew, W.L., Felsenstein, D. & Hirsch, M.S. Sensitivity of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J. Infect. Dis. 152, 833-834 (1985).
4. Robbins, B.L., Connelly, M.C., Marshall, D.R., Srinivas, R.V. & Fridland, A. A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent. Mol. Pharmacol. 47, 391-397 (1995).
5. Boer, R., Haas, S. & Schodl, A. Influence of dexniguldipine-HCI on rhodamine-123 accumulation in a multidrug-resistant leukaemia cell line: comparison with other chemosensitisers. Euro. Int. Cancer 30A, 1117-1123 (1994).
6. Kool, M. et al. Analysis of expression of cMOAT (MRP2) MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57, 3537-3547 (1997).
7. Wolverton, J.S., Danks, M.K., Schmidt, C.A. & Beck, W. T. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells. Cancer Res. 49, 2422-2426 (1989).
8. Hirsch, M.S. et al. Antiretroviral drug resistance testing in adults with HIV infection. J. Am. Med. Assoc. 279, 1984-1991 (1998).
9. Balzarini, J. et al. The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochem. Pharm. 37, 897-903 (1988).
10. Furman, P.A. et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA. 83, 8333-8337 (1986).
11. Lavie, A. et al. The bottleneck in AZT activation. Nature Med. 3, 922-924 (1997).
12. Balzarini, J., Degreve, B. & DeClercq, E. Improving AZT efficacy. Nature Med. 4, 132 (1998).
13. Levy, J.A. in Viral Oncogenesis and Cell Differentiation (eds. Diamond, L. & Wolman, S.R.) 58-68 (New York Academy of Sciences, New York, 1989).
14. Kepler, T.B. & Perelson, A.S. Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc. Natl. Acad. Sci. USA 95, 11514-11519 (1998).
15. Medina, D.J. et al. Sanctuary growth of human immunodeficiency virus in the presence of 3′-azido-3′-deoxythymidine. J. Virol. 69, 1606-1611 (1995).
16. Karmata, P., Compton, M.L. & Paborsky, L.R. Mechanism of anti-proliferative activity of PMEG, a novel acyclic nucleotide analog. Proc. Amer. Assoc. Cancer Ries. 39, 3198 (1998).
17. Loe, D.W., Deeley, R.G. & Cole, S.P.C. Biology of the multidrug resistance-associated protein, MRP. Euro Jnl. Cancer 32A, 945-957 (1996).
18. Srinivas, R.V., Connely, M. & Fridland, A. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) inhibits HIV-1 replication in epithelial cells, but not T-lymphocytes. Antiviral Res. 35, 23-27 (1997).
19. Robbins, B.L., Waibel, B.H. & Fridland, A. Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology. Antimicrob. Agents Chemother. 40, 2651-2654 (1996).
20. Pisarev, V.M., Lee, S-H., Connelly, M.C. & Fridland, A. Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication. Mol. Pharmacol. 52, 63-68 (1997).
21. Schuetz, J.D., Molowa, D.T. & Guzelian, P.S. Characterisation of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver. Arch. Biochem. Biophys. 274, 355-365 (1989).
22. Schuetz, E.G., Beck, W.T. & Schuetz, J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49, 311-318 (1996).